Alerts will be sent to your verified email
Verify EmailKABRADG
|
Kabra Drugs
|
Phaarmasia
|
Vivo Bio Tech
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
36.01 % | 0.46 % | 7.43 % |
|
5yr average Equity Multiplier
|
-0.87 | 2.3 | 2.24 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 0.96 | 0.43 |
|
5yr Avg Net Profit Margin
|
0.0 | -4.04 % | 8.3 % |
|
Price to Book
|
2.19 | 5.12 | 0.6 |
|
P/E
|
13.26 | 3.12 | 12.93 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | -236.72 Days | 90.56 Days |
|
Inventory Days
|
0.0 | 79.69 Days | 72.05 Days |
|
Days Receivable
|
0.0 | 83.55 Days | 90.11 Days |
|
Days Payable
|
0.0 | 340.86 Days | 88.09 Days |
|
5yr Average Interest Coverage Ratio
|
-1068.45 | -92.68 | 2.13 |
|
5yr Avg ROCE
|
21.53 % | -8.87 % | 13.85 % |
|
5yr Avg Operating Profit Margin
|
0.0 | -5.39 % | 39.67 % |
|
5 yr average Debt to Equity
|
-1.45 | 0.0 | 1.08 |
|
5yr CAGR Net Profit
|
43.36 % | n/a | 5.09 % |
|
5yr Average Return on Assets
|
-21.34 % | -3.86 % | 3.6 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 73.51 % | 35.43 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | -6.65 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kabra Drugs
|
Phaarmasia
|
Vivo Bio Tech
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|